<DOC>
	<DOCNO>NCT02262793</DOCNO>
	<brief_summary>To investigate relative bioavailability telmisartan respectively dipyridamole concomitant administration 80 mg telmisartan Micardis® 25 mg acetylsalicylic acid ( ASA ) /200 mg extend release ( ER ) dipyridamole ( DP ) Aggrenox® ( Test 1 ) relative ER-DP Aggrenox® alone ( Reference 1 ) , respectively relative telmisartan Micardis® alone ( Reference 2 ) . To investigate relative bioavailability dipyridamole respectively telmisartan administer 25 mg ASA/200 mg ER-DP 30 minute intake 80 mg telmisartan ( Test 2 ) relative dipyridamole Aggrenox® alone ( Reference 1 ) , respectively relative telmisartan Micardis® alone ( Reference 2 ) .</brief_summary>
	<brief_title>Relative Bioavailability Telmisartan Dipyridamole After Co-administration Compared Bioavailability Telmisartan Dipyridamole Alone Healthy Female Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>1 . Healthy female male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , HR ) , 12lead ECG , clinical laboratory test No find deviate normal clinical relevance No evidence clinically relevant concomitant disease 2 . Age ≥21 Age ≤65 year 3 . BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Surgery gastrointestinal tract ( except appendectomy ) 3 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 4 . History relevant orthostatic hypotension , faint spell blackout . 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 7 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 8 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 9 . Participation another trial investigational drug within two month prior administration trial 10 . Smoker ( 10 cigarettes/day 3 cigars/day 3 pipes/day ) 11 . Inability refrain smoke trial day 12 . Alcohol abuse ( 60 g/day ) 13 . Drug abuse 14 . Blood donation ( 100 mL within four week prior administration trial ) 15 . Excessive physical activity ( within one week prior administration trial ) 16 . Any laboratory value outside reference range clinical relevance 17 . Inability comply dietary regimen study centre 18 . History hereditary fructose intolerance 19 . History familial bleeding disorder 20 . Veins unsuited i.v . puncture either arm ( e.g . vein difficult locate , access puncture , vein tendency rupture puncture , etc . ) 21 . Inability comply investigator instruction For female subject : 22 . Pregnancy 23 . Positive pregnancy test 24 . No adequate contraception e.g . oral contraceptive , sterilization , intrauterine device ( IUD ) 25 . Inability maintain adequate contraception whole study period 26 . Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>